World of DTC Marketing
MARCH 17, 2021
The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the whole industry is winning praise for co-operation” However, the bump in reputation will be short-lived because companies need to earn the public’s trust every day, and pharma is already damaging their perception with people.
Clarivate
MAY 31, 2023
A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 15, 2022
The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database. AbbVie reported a 22.7%
Pharmaceutical Technology
MAY 16, 2023
trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.
pharmaphorum
AUGUST 4, 2022
The deal comes as Amgen has been under pressure from competition to its big-selling arthritis therapy Enbrel (etanercept) and blood cell booster Epogen (epoetin alfa), and a patent expiry for psoriasis blockbuster Otezla (apremilast) in 2028. Amgen said it expects the deal to close in the fourth quarter of 2022.
pharmaphorum
AUGUST 2, 2022
Now, Roche has an opportunity to add ease of administration to the competitive profile of Tecentriq, reducing the time patients have to spend in clinics and potentially reducing the cost of treatment. Results from a trial in first-line NSCLC are due in early 2023.
pharmaphorum
OCTOBER 10, 2022
The pharma group said earlier this year it is hoping for eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, and thrombosis as well as PAH, that will swell its sales from in the category to $10 billion around the end of the decade.
Expert insights. Personalized for you.
186 
Let's personalize your content